Evidence map›Paper›PMID 29320517›Full record

ArticlePloS one2018

Explaining the decline in coronary heart disease mortality rates in the Slovak Republic between 1993-2008.

Marek Psota, Piotr Bandosz, Eva Gonçalvesová, Mária Avdičová, Mária Bucek Pšenková, Martin Studenčan, Jarmila Pekarčíková, Simon Capewell, Martin O'Flaherty

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Marek PsotaDepartment of Public Health, Faculty of Health Sciences and Social Work, Trnava University in Trnava, Trnava, Slovak Republic.ORCID 0000-0001-5943-0978
Piotr BandoszDepartment of Public Health and Policy, Institute of Psychology, Health & Society, University of Liverpool, Liverpool, United Kingdom.
Eva GonçalvesováDepartment of Heart Failure and Transplantation, National Institute of Cardiovascular Diseases, Bratislava, Slovak Republic.
Mária AvdičováRegional Authority of Public Health in Banská Bystrica, Banská Bystrica, Slovak Republic.
Mária Bucek PšenkováPHARM-In, spol. s r.o., Bratislava, Slovak Republic.
Martin StudenčanCardiac centre of Faculty Hospital J.A.Reiman, Prešov, Slovak Republic.
Jarmila PekarčíkováDepartment of Public Health, Faculty of Health Sciences and Social Work, Trnava University in Trnava, Trnava, Slovak Republic.
Simon CapewellDepartment of Public Health and Policy, Institute of Psychology, Health & Society, University of Liverpool, Liverpool, United Kingdom.
Martin O'FlahertyDepartment of Public Health and Policy, Institute of Psychology, Health & Society, University of Liverpool, Liverpool, United Kingdom.
University of Liverpool · GBUniversity of Trnava · SKPublic Health Authority of the Slovak Republic · SK

Funding

Medical Research Council G0900847
6 · The paper itself

Abstract

objectiveBetween the years 1993 and 2008, mortality rates from coronary heart disease (CHD) in the Slovak Republic have decreased by almost one quarter. However, this was a smaller decline than in neighbouring countries. The aim of this modelling study was therefore to quantify the contributions of risk factor changes and the use of evidence-based medical therapies to the CHD mortality decline between 1993 and 2008.

methodsWe identified, obtained and scrutinised the data required for the model. These data detailed trends in the major population cardiovascular risk factors (smoking, blood pressure, total cholesterol, diabetes prevalence, body mass index (BMI) and physical activity levels), and also the uptake of all standard CHD treatments. The main data sources were official statistics (National Health Information Centre and Statistical Office of the Slovak Republic) and national representative studies (AUDIT, SLOVAKS, SLOVASeZ, CINDI, EHES, EHIS). The previously validated IMPACT policy model was then used to combine and integrate these data with effect sizes from published meta-analyses quantifying the effectiveness of specific evidence-based treatments, and population-wide changes in cardiovascular risk factors. Results were expressed as deaths prevented or postponed (DPPs) attributable to risk factor changes or treatments. Uncertainties were explored using sensitivity analyses.

resultsBetween 1993 and 2008 age-adjusted CHD mortality rates in the Slovak Republic (SR) decreased by 23% in men and 26% in women aged 25-74 years. This represented some 1820 fewer CHD deaths in 2008 than expected if mortality rates had not fallen. The IMPACT model explained 91% of this mortality decline. Approximately 50% of the decline was attributable to changes in acute phase and secondary prevention treatments, particularly acute and chronic treatments for heart failure (≈12%), acute coronary syndrome treatments (≈9%) and secondary prevention following AMI and revascularisation (≈8%). Changes in CHD risk factors explained approximately 41% of the total mortality decrease, mainly reflecting reductions in total serum cholesterol. However, other risk factors demonstrated adverse trends and thus generated approximately 740 additional deaths.

conclusionOur analysis suggests that approximately half the CHD mortality fall recently observed in the SR may be attributable to the increased use of evidence-based treatments. However, the adverse trends observed in all the major cardiovascular risk factors (apart from total cholesterol) are deeply worrying. They highlight the need for more energetic population-wide prevention policies such as tobacco control, reducing salt and industrial trans fats content in processed food, clearer food labelling and regulated marketing of processed foods and sugary drinks.

Indexed as

AdultAgedAngioplastyCardiovascular AgentsCardiovascular DiseasesCholesterolCoronary Artery BypassCoronary DiseaseDiabetes MellitusDietEvidence-Based MedicineExerciseFemaleHumansMaleMeta-Analysis as TopicCardiovascular AgentsCholesterol

Identifiers

PMID29320517
PMCPMC5761866
OpenAlexW2784169243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.